Strategic Diagnostics Board Approves $3M Stock Repurchase Program | GenomeWeb
NEW YORK (GenomeWeb News) - Strategic Diagnostics said today that its board of directors has approved a program to repurchase up to $3 million of the company's outstanding shares of common stock over the next 12 months.
"We believe that our stock price does not reflect our belief in the long term value of Strategic Diagnostics,” Francis DiNuzzo, president and CEO, said in a statement. “A repurchase program will benefit SDI's shareholders and demonstrates our board's and management team's confidence in our business.”

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.